中国临床药理学杂志2019，Vol.35Issue(8)：816-820,5.DOI:10.13699/j.cnki.1001-6821.2019.08.026
雷珠单抗治疗新生血管性老年性黄斑变性的药物基因学研究进展
Research advance on pharmacogenomics of ranibizumab in the treatment of age-related macular degeneration
戴玉洋 1赵秀丽1
作者信息
- 1. 首都医科大学 附属北京同仁医院 国家药物临床试验机构,北京 100730
- 折叠
摘要
Abstract
Age-related macular degeneration is one of eye diseases that may cause blindness in the elderly in China. Ranibizumab is recommended as the first-line treatment for neovascular age-related macular degeneration. However,there are individual differences in the clinical efficacy,and almost ten percent of the patients are sufferring from ineffectiveness. Anti-vascular endothelial growth factor(VEGF) drug effects are affected by multiple factors,and drug gene polymorphism may be an important factor leading to treatment failure. This paper reviews the researches of ranibizumab pharmacogenomics,expecting to provide evidences to support the individualized treatment of age-related macular degeneration.关键词
老年性黄斑变性/雷珠单抗/血管内皮生长因子/基因多态性Key words
age-related macular degeneration/ranibizumab/vascular endothelial growth factor/gene polymorphism分类
医药卫生引用本文复制引用
戴玉洋,赵秀丽..雷珠单抗治疗新生血管性老年性黄斑变性的药物基因学研究进展[J].中国临床药理学杂志,2019,35(8):816-820,5.
